These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30073478)

  • 1. Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.
    Zhong BY; Ni CF; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Teng GJ
    Cardiovasc Intervent Radiol; 2018 Dec; 41(12):1867-1876. PubMed ID: 30073478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
    Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT
    Gastroenterology; 2014 Jun; 146(7):1691-700.e3. PubMed ID: 24583061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.
    Sohn JH; Duran R; Zhao Y; Fleckenstein F; Chapiro J; Sahu S; Schernthaner RE; Qian T; Lee H; Zhao L; Hamilton J; Frangakis C; Lin M; Salem R; Geschwind JF
    Clin Gastroenterol Hepatol; 2017 May; 15(5):746-755.e4. PubMed ID: 27847278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
    Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
    Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barcelona Clinic Liver Cancer outperforms Hong Kong Liver Cancer staging of hepatocellular carcinoma in multiethnic Asians: Real-world perspective.
    Li JW; Goh BG; Chang PE; Tan CK
    World J Gastroenterol; 2017 Jun; 23(22):4054-4063. PubMed ID: 28652658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
    Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
    Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
    Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
    Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
    Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma.
    Kohla M; Ashour R; Taha H; El-Abd O; Osman M; Abozeid M; ELKhadry SW
    BMC Gastroenterol; 2024 Sep; 24(1):318. PubMed ID: 39294585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms.
    Lee YS; Seo YS; Kim JH; Lee J; Kim HR; Yoo YJ; Kim TS; Kang SH; Suh SJ; Joo MK; Jung YK; Lee BJ; Yim HJ; Yeon JE; Kim JS; Park JJ; Um SH; Bak YT; Byun KS
    Gut Liver; 2018 Jan; 12(1):94-101. PubMed ID: 28873509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.
    Yan X; Fu X; Cai C; Zi X; Yao H; Qiu Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1180-6. PubMed ID: 26067223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore.
    Selby LK; Tay RX; Woon WW; Low JK; Bei W; Shelat VG; Pang TC; Junnarkar SP
    J Hepatobiliary Pancreat Sci; 2017 Mar; 24(3):143-152. PubMed ID: 28012284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.
    Zhong BY; Jiang JQ; Sun JH; Huang JT; Wang WD; Wang Q; Ding WB; Zhu XL; Ni CF
    J Clin Transl Hepatol; 2023 Nov; 11(6):1321-1328. PubMed ID: 37719966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
    Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.
    Zhong JH; Peng NF; You XM; Ma L; Xiang X; Wang YY; Gong WF; Wu FX; Xiang BD; Li LQ
    Oncotarget; 2017 Mar; 8(11):18296-18302. PubMed ID: 28407686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
    Heinrich S; Sprinzl M; Schmidtmann I; Heil E; Koch S; Czauderna C; Heinrich B; Philippe P Diggs L; Wörns MA; Kloeckner R; Galle PR; Marquardt JU; Weinmann A
    United European Gastroenterol J; 2020 May; 8(4):444-452. PubMed ID: 32213028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Hong Kong Liver Cancer Staging System in Europe.
    Kolly P; Reeves H; Sangro B; Knöpfli M; Candinas D; Dufour JF
    Liver Int; 2016 Jun; 36(6):911-7. PubMed ID: 26677809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.